Toxicokinetic Profiling of VRP-034: Evaluating its Potential in Mitigating Polymyxin B-Associated Nephrotoxicity.

This study assessed the nephrotoxicity and toxicokinetic profile of VRP-034 (novel formulation of polymyxin B [PMB]) compared to marketed PMB over a seven-day repeat-dose regimen. Three objectives were pursued: evaluating PMB pharmacokinetics in both groups, alongside assessing VRP-034's impact on mitigating PMB-associated kidney injury; analyzing kidney injury reversibility; and validating novel kidney injury biomarkers against traditional markers using histopathology scoring. 68 Sprague-Dawley rats were divided into three groups: 30 each for marketed PMB and VRP-034 groups, and 8 for control.